Spyre Therapeutics Q2 EPS $(0.49) Beats $(0.77) Estimate

Spyre Therapeutics (NASDAQ: SYRE) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.77) by 35.95 percent. This is a 16.95 percent increase over losses of $(0.59) per share from the same period last year.